质子治疗再程放疗用于复发食管及食管胃交界部恶性肿瘤:质子协作组多机构前瞻性登记试验结果
本研究基于质子协作组多中心前瞻性登记数据,分析了31例既往接受光子放疗后局部区域复发食管癌患者接受质子束再程放疗的毒性与疗效。中位随访7.2个月,6个月局部控制率、无远处转移生存率和总生存率分别为80.5%、83.4%和69.1%,急性≥3级毒性发生率为23%,未报告≥3级晚期毒性。作者认为急性毒性可接受且疾病控制率令人鼓舞,但受患者预后差限制,需进一步研究评估长期获益与毒性。
要点
- 31例既往光子放疗后复发食管癌患者接受质子再程放疗,67.7%同步化疗。
- 6个月局部控制率80.5%、无远处转移生存率83.4%、总生存率69.1%。
- 急性≥3级毒性23%,含1例急性5级食管出血毒性,未报告≥3级晚期毒性。
核心结论
- 在迄今最大宗质子再程放疗用于复发食管癌的报告里,观察到急性毒性可接受且疾病控制率令人鼓舞。
- 这些发现受限于患者预后差、死亡风险高。
- 需要进一步研究以更好地评估质子束治疗在该特定人群中的长期获益与毒性。
研究设计与样本
- 分析质子协作组前瞻性多中心登记中既往接受光子放疗后接受质子束再程放疗的复发食管癌患者。
- 2012年至2020年间,31例患者在7家机构接受再程放疗,采用均匀扫描/被动散射(61.3%)或笔形束扫描(38.7%)质子束治疗。
- 收集患者/肿瘤特征、治疗细节、结局和毒性,采用Kaplan-Meier法估算局部控制、无远处转移生存和总生存,事件时间自再程放疗开始计算。
主要发现
- 既往放疗中位剂量50.4 Gy(范围37.5-110.4),质子再程放疗中位剂量48.6 Gy(相对生物效应)(范围25.2-72.1),累积中位剂量99.9 Gy(范围79.1-182.5)。
- 12.9%的患者既往接受过2程放疗,67.7%接受质子束治疗同步化疗,中位随访7.2个月(范围0.9-64.7)。
- 质子束治疗后,16.7%仅局部区域复发,11.1%仅远处复发,16.7%局部区域和远处复发。
- 6个月局部控制率、无远处转移生存率和总生存率分别为80.5%、83.4%和69.1%;1年分别为67.1%、83.4%和27%。
- 急性≥3级毒性发生于23%的患者,1例急性5级毒性继发于食管出血、不确定与再程放疗或疾病进展相关;未报告≥3级晚期毒性。
临床怎么用
- 原文未据此给出推荐。
局限性
- 这些发现受限于患者预后差、死亡风险高。
- 需要进一步研究以更好地评估质子束治疗在该特定人群中的长期获益与毒性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Treatment options for recurrent esophageal cancer (EC) previously treated with radiation therapy (RT) are limited. Reirradiation (reRT) with proton beam therapy (PBT) can offer lower toxicities by limiting doses to surrounding tissues. In this study, we present the first multi-institutional series reporting on toxicities and outcomes after reRT for locoregionally recurrent EC with PBT. METHODS AND MATERIALS: Analysis of the prospective, multicenter, Proton Collaborative Group registry of patients with recurrent EC who had previously received photon-based RT and underwent PBT reRT was performed. Patient/tumor characteristics, treatment details, outcomes, and toxicities were collected. Local control (LC), distant metastasis-free survival (DMFS), and overall survival (OS) were estimated using the Kaplan-Meier method. Event time was determined from reRT start. RESULTS: Between 2012 and 2020, 31 patients received reRT via uniform scanning/passive scattering (61.3%) or pencil beam scanning (38.7%) PBT at 7 institutions. Median prior RT, PBT reRT, and cumulative doses were 50.4 Gy (range, 37.5-110.4), 48.6 Gy (relative biological effectiveness) (25.2-72.1), and 99.9 Gy (79.1-182.5), respectively. Of these patients, 12.9% had 2 prior RT courses, and 67.7% received PBT with concurrent chemotherapy. Median follow-up was 7.2 months (0.9-64.7). Post-PBT, there were 16.7% locoregional only, 11.1% distant only, and 16.7% locoregional and distant recurrences. Six-month LC, DMFS, and OS were 80.5%, 83.4%, and 69.1%, respectively. One-year LC, DMFS, and OS were 67.1%, 83.4%, and 27%, respectively. Acute grade ≥3 toxicities occurred in 23% of patients, with 1 acute grade 5 toxicity secondary to esophageal hemorrhage, unclear if related to reRT or disease progression. No grade ≥3 late toxicities were reported. CONCLUSIONS: In the largest report to date of PBT for reRT in patients with recurrent EC, we observed acceptable acute toxicities and encouraging rates of disease control. However, these findings are limited by the poor prognoses of these patients, who are at high risk of mortality. Further research is needed to better assess the long-term benefits and toxicities of PBT in this specific patient population.
引用
- Hotca A, Sindhu KK, Lehrer EJ, et al. Reirradiation With Proton Therapy for Recurrent Malignancies of the Esophagus and Gastroesophageal Junction: Results of the Proton Collaborative Group Multi-Institutional Prospective Registry Trial. Adv Radiat Oncol. 2024. PMID: 38596455. doi:10.1016/j.adro.2024.101459
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。